Vallon Pharmaceuticals (VLON) Announces Review of Strategic Alternatives

  • July 29, 2022

POTENTIAL DEAL DETAILS

StockVallon Pharmaceuticals, Inc.SymbolVLON
Date Announced04/22/2022Source Press Release
TypeCompany Seeking Strategic Alternatives

Vallon Pharmaceuticals, Inc. (VLON), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, announced it has engaged Ladenburg Thalmann & Co. Inc. to evaluate strategic alternatives for the Company with the goal of maximizing shareholder value.

Update(s):

May 9, 2022: Subsequent to the quarter, Vallon engaged Ladenburg Thalmann & Co. Inc. to evaluate strategic alternatives for the Company, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets.

July 28, 2022: Second quarter 2022: The review of strategic alternatives remains ongoing and could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets;

Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.